Insulin Sensitivity

all catalysts(0)

nothing on the calendar yet

News(4)

• Zealand's stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3
  A phase 3 trial of Boehringer Ingelheim’s survodutide in people with obesity and Type 2 diabetes has met its co-primary endpoints. Yet, with the readout echoing earlier data that underwhelmed analy…
  fiercebiotech · 1d ago
• Roche cuts muscle-sparing obesity drug after mid-stage disappointment
  Roche’s anti-myostatin therapy emugrobart is unlikely to elicit meaningful weight loss, according to an interim mid-stage analysis, prompting the pharma to return the asset rights to its subsidiary…
  biospace · 2d ago
• Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui
  Novo’s ongoing efforts to rejuvenate its pipeline have seen the Big Pharma turn to one of the most in-demand drug developers in China.
  fiercebiotech · 3d ago
• Why Roche is 'really excited' about a UCN2 analog for obesity after seeing preclinical data
  Roche has decided to pay $190 million upfront for an unusual obesity mechanism after viewing preclinical data that “clearly suggests” the modality can reduce weight while preserving lean muscle, Fi…
  fiercebiotech · 1mo ago